Efficacy of vemurafenib, a selective BRAFV600E inhibitor, in combination with a MEK inhibitor in BRAFV600E colorectal cancer models.

被引：1
|
作者：
Higgins, Brian
Kolinsky, Kenneth Daniel
Yang, Hong
Kim, Min Jung
Li, Jia Kui
Go, Zenaida
Packman, Kathryn
Bollag, Gideon
Su, Fei
机构：
[1] Hoffmann Roche Inc, Pharma Res & Early Dev, Nutley, NJ USA
[2] Plexxikon Inc, Berkeley, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 04期
关键词：
D O I：
10.1200/jco.2012.30.4_suppl.488
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
488
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Insight on BRAFV600E mutated colorectal cancer immune microenvironment
    Hassan Mohammed Abushukair
    Sara Mu'amar Zaitoun
    Anwaar Saeed
    [J]. World Journal of Gastrointestinal Oncology, 2022, 14 (06) : 1213 - 1215
  • [22] Beta-catenin in the course of aquired resistance to the BRAFV600E inhibitor vemurafenib in malignant melanoma
    Sinnberg, T.
    Makino, E.
    Poetz, O.
    Rothbauer, U.
    Niessner, H.
    Beck, D.
    Krueger, M.
    Meier, F.
    Schittek, B.
    [J]. EXPERIMENTAL DERMATOLOGY, 2014, 23 (03) : E50 - E50
  • [23] Synergistic Combination of Novel Tubulin Inhibitor ABI-274 and Vemurafenib Overcomes Vemurafenib Acquired Resistance in BRAFV600E Melanoma
    Wang, Jin
    Chen, Jianjun
    Miller, Duane D.
    Li, Wei
    [J]. MOLECULAR CANCER THERAPEUTICS, 2014, 13 (01) : 16 - 26
  • [24] HER inhibitor promotes BRAF/MEK inhibitor-induced redifferentiation in papillary thyroid cancer harboring BRAFV600E
    Cheng, Lingxiao
    Jin, Yuchen
    Liu, Min
    Ruan, Maomei
    Chen, Libo
    [J]. ONCOTARGET, 2017, 8 (12) : 19843 - 19854
  • [25] MAPK inhibition in BRAFV600E CRC
    Kotsiliti, Eleni
    [J]. NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2023, 20 (4) : 201 - 201
  • [26] Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation
    Hong, David S.
    Morris, Van K.
    El Osta, Badi
    Sorokin, Alexey V.
    Janku, Filip
    Fu, Siqing
    Overman, Michael J.
    Piha-Paul, Sarina
    Subbiah, Vivek
    Kee, Bryan
    Tsimberidou, Apostolia M.
    Fogelman, David
    Bellido, Jorge
    Shureiqi, Imad
    Huang, Helen
    Atkins, Johnique
    Tarcic, Gabi
    Sommer, Nicolas
    Lanman, Richard
    Meric-Bernstam, Funda
    Kopetz, Scott
    [J]. CANCER DISCOVERY, 2016, 6 (12) : 1352 - 1365
  • [27] MITOCHONDRIAL METABOLIC REPROGRAMMING OF MELANOMA CELLS EXPOSED TO BRAFV600E INHIBITOR
    Kluza, J.
    Jendoubi, M.
    Corazao-Rozas, P.
    Andre, F.
    Jonneaux, A.
    Guerreschi, P.
    Formstecher, P.
    Mortier, L.
    Marchetti, P. H. I.
    [J]. ANNALS OF ONCOLOGY, 2013, 24 : 30 - 30
  • [28] Resistance to BRAF and MEK inhibitors in BRAFV600E mutant melanoma
    Patel, Hima
    Mishra, Rosalin
    Joan, Garrett
    [J]. CANCER RESEARCH, 2019, 79 (13)
  • [29] A Combinatorial Strategy for Targeting BRAFV600E-Mutant Cancers with BRAFV600E Inhibitor (PLX4720) and Tyrosine Kinase Inhibitor (Ponatinib)
    Ghosh, Chandrayee
    Kumar, Suresh
    Kushchayeva, Yevgeniya
    Gaskins, Kelli
    Boufraqech, Myriem
    Wei, Darmood
    Gara, Sudheer Kumar
    Zhang, Lisa
    Zhang, Ya-qin
    Shen, Min
    Mukherjee, Sanjit
    Kebebew, Electron
    [J]. CLINICAL CANCER RESEARCH, 2020, 26 (08) : 2022 - 2036
  • [30] cAMP signaling in BRAFV600E melanoma
    Rodriguez, Carlos I.
    [J]. CANCER RESEARCH, 2014, 74 (19)
12345